A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Prospective, multicenter, single arm, phase II study, to evaluate the efficacy of the combination rituximab-golcadomide as a chemo free approach in a population of older patients with new diagnosis of DLBCL, defined as frail according to a sGA evaluation and not candidate for the standard R-CHOP (or R-CHOP like) treatments.

Trial Details

NCT ID
NCT06835530
Phase
PHASE2
Sponsor
Fondazione Italiana Linfomi - ETS
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Rituximab + Golcadomide (CC-99282)
Locations (sample)
  • Alessandria, Alessandria, Italy|44.90924,8.61007
  • Pescara, Pescara, Italy|42.4584,14.20283
  • Ancona, Italy|43.60717,13.5103
  • Avellino, Italy|40.91494,14.79103
  • Aviano, Italy|46.07056,12.59472

Key Eligibility Criteria

  • Able to provide written informed consent form approved by the National Ethics Committee (NEC) prior to the initiation of any screening or study- sp…
  • Histologically documented diagnosis of DLBCL as defined in the 5th edition of the World Health Organization (WHO) classification (2022)
  • Previously untreated
  • Frail patients defined as follows (Appendix A-D): Age ≥ 80 years: activity of daily living (ADL) \< 6 residual functions and/or Instrumental activi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →